ARIAD Pharmaceuticals (ARIA)

Add to Watchlists
Create an Alert
7.095 +0.41  +6.05% NASDAQ Apr 16, 5:00PM BATS Real time Currency in USD
View Full Chart
ARIA Price Chart
View All Events

ARIA Events

Date Type Description
Feb 25 Misc Q4 FY 2013 ARIAD Pharmaceuticals, Inc. Earnings Conference Call
Feb 25 Earnings Q4 FY 2013 ARIAD Pharmaceuticals, Inc. Earnings Results. Estimate: -0.46.
Nov 06 Misc Ariad Pharmaceuticals, Inc. Q3 2013 Earnings Conference Call
Nov 06 Earnings Ariad Pharmaceuticals, Inc. Q3 2013 Earnings Release. Estimate: -0.44.
Oct 31 Misc Investor Conference Call Today, October 31, at 9:00 a.m. e.t. Cambridge, Mass.--(business Wire)--oct. 31, 2013-- Ariad Pharmaceuticals, Inc. (Nasdaq:aria) Today Announced That It Is Temporarily Suspending the Marketing and Commercial Distribution Of
Oct 09 Misc Ariad Pharmaceuticals, Inc. Investor Conference Call
Sep 28 Misc Ariad Esmo Conference Call
Sep 28 Misc Ariad Announces Updated Data on Ap26113 to Be Presented at the European Cancer Congress 2013 Meeting
Aug 07 Misc Ariad to Host Conference Call and Webcast Discussion of Second Quarter 2013 Financial Results on August 7, 2013
Aug 07 Earnings Second Quarter 2013 Financial Results on August 7, 2013. Estimate: -0.40.
View All Performance Charts

ARIA Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ARIAD Pharmaceuticals is down 60.14% over the last year vs S&P 500 Total Return up 22.52%, Endocyte up 42.07%, and Jazz Pharmaceuticals up 155.4%.

Get Quote for

PDF Report for ARIA

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download ARIA Pro Report PDF
Advertisement

Portfolio Strategies Featuring ARIA

Did ARIAD Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

ARIA Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: Massachusetts
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Biological Product (except Diagnostic) Manufacturing
  • NAICS Code: 325414
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

ARIAD Pharmaceuticals, Inc. is a small pharmaceutical company focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. It has three products: Ridaforolimus, Ponatinib and AP26113. Its approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. The company is located in Cambridge, Massachusetts. It was established in 1991 by Larry Bock, David Blech and Harvery Berger. It has strong partnerships with Merck.

Recent Quotes

Symbol Price Chg Chg % Market Cap
ARIA 7.095 +0.41 +6.05% 1.322B
Create Watchlist from Quotes
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.